title: Study of immune cells involved in the antitumor effect of kefir in a murine breast cancer model.
abstract: Administration of kefir and a kefir cell-free fraction (KF) to mice injected with breast tumor cells produced, locally in the mammary gland, different profiles of cells secreting cytokines. Here, the immune cell populations in mammary glands affected by the cyclic consumption of kefir or KF for 2 or 7 d were evaluated using a breast tumor model. Apoptosis was also assayed as another mechanism involved in tumor growth delay. The rate development of tumor cells, IgA(+) cells, and CD4+ and CD8+ T lymphocytes was monitored in mammary gland tissues. The number of Bcl-2(+) cells in the mammary gland was compared with the apoptosis observed in the tumor. Two-day cyclical administration of both products delayed tumor growth and increased the number of IgA(+) cells in the mammary gland. Changes in the balance between CD4+ and CD8+ cells in the mammary gland were observed in mice from the group fed KF cyclically for 2 d, such that the number of CD4+ cells increased when the number of CD8+ cells remained constant. Mice that received 2-d cyclic administration of KF showed significant increases in the number of apoptotic cells and decreases in Bcl-2(+) cells in the mammary gland, compared with the tumor control group. The present study allows a better understanding of the mechanisms (immune and nonimmune) involved in the antitumor effect observed in mice administered kefir or KF. The importance of nonmicrobial components released during milk fermentation to obtain the beneficial antitumor effects is also reported.
authors: Départment de Chimie-Biochimie, Université de Moncton, Moncton, New Brunswick, Canada E1A 3E9.
authors: A
authors: A
authors: de Moreno de Leblanc
authors: C
authors: C
authors: Matar
authors: E
authors: E
authors: Farnworth
authors: G
authors: G
authors: Perdigón
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D017209:Apoptosis; D001943:Breast Neoplasms / Q000276:immunology / Q000517:prevention & control*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D045744:Cell Line, Tumor; D043302:Cultured Milk Products / Q000276:immunology*; D019587:Dietary Supplements; D004195:Disease Models, Animal; D005260:Female; D007070:Immunoglobulin A / Q000276:immunology; D008321:Mammary Glands, Animal / Q000166:cytology / Q000276:immunology; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D007070:Immunoglobulin A; D019253:Proto-Oncogene Proteins c-bcl-2